NCT06677190
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
At risk: Primary completion moved at least 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 30, 2026 to Dec 31, 2027 Show 7 more changesShow less
- Eligibility criteria expanded, about 52 words
- Enrollment closed, study ongoing
- Study completion pushed from Jun 30, 2029 to Jun 30, 2030
- Secondary endpoints: details revised at 1 of 4 entries
- Study description revised
- Site details revised at 2 of 2 sites
- Collaborators: details revised at 1 of 1 entry
- Notable Eligibility criteria expanded, about 14 words
- Study description expanded, about 12 words
- Study title expanded, about 2 words
- Minor Start date: Dec 1, 2024 to Dec 20, 2024
- Site contacts updated at 2 of 2 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 1, 2025 to Dec 1, 2024
- Site details revised at 2 of 2 sites
- Notable Eligibility criteria expanded, about 16 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
15 participants will be enrolled for Stage 1 and will complete: * Baseline in-clinic visit * Imaging every 2 cycles * ECG on Day 1 of each cycle * Cycle 1 through End of Treatment: * Day 1 through 28 of 28 day cycle: Predetermined dose of Belzutifan 1x daily. * Day 15 of 28 day cycle: in-clinic visit * Cycle 2 Day 15 of 28 day cycle: in-clinic visit * End of treatment visit with ECG, blood tests, and imaging. * 30 Day post-treatment visit * Long-term follow up: every 6 months for 3 years * If 3 or more participants have objective response OR 2 or more participants are progression-free at 6 months, the study will enroll an additional 14 participants for Stage 2. Otherwise, enrollment will stop if there are less than 3 participants with objective response AND less than 2 participants are progression-free at 6 months.
Drugs: Belzutifan
Sites
2 sites in 1 country